Active Research Studies: Breast Cancer

Comprehensive Cancer Centers is currently running the following Phase II and Phase III clinical research studies for breast cancers:

Phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer
Study#: i2639 Phase III
Contact Us: For information about this clinical study, Email Us, or use our form field.

An International, Phase 3, Multicenter, Randomized, Open- Label Trial Comparing Eribulin with and without Balixafortide in Patients with Locally Recurrent and Metastatic Breast Cancer
Study#: i2665 Phase III
Contact Us: For information about this clinical study, Email Us, or use our form field.

A phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of 400 mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- and postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received no prior therapy for advanced disease.
Study#: 19004 Phase: II
Contact Us: For information about this clinical study, Email Us, or use our form field.

A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo
Study#: i2757 Phase: III
Contact Us: For information about this clinical study, Email Us, or use our form field.

Randomized. Double-blind. Phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer
Study#: i2738 Phase: III
Contact Us: For information about this clinical study, Email Us, or use our form field.

Phase I/II trial of Ibrutinib plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
Study#: 14059 Phase I/II
Contact Us: For information about this clinical study, Email Us, or use our form field.